{"transactions":[{"id":724981,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-29T20:10:56.000Z","date":"2026-06-25","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":26000,"derivative":{"exercise_price":34.09,"exercise_date":"2027-06-25","expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001586785-26-000008","document":"form4-06292026_080652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000158678526000008/form4-06292026_080652.xml","form_type":"4"}},{"id":763302,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:10:07.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":100200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents performance stock units (\"PSUs\") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":190314,"source":{"system":"sec-edgar","filing":"0001586785-26-000006","document":"form4-05262026_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000158678526000006/form4-05262026_040501.xml","form_type":"4"}},{"id":823946,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-31T20:11:19.000Z","date":"2026-03-28","kind":"exercise","planned":false,"acquired":false,"shares":64866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":64867,"derivative":{"underlying":"Common Stock","underlying_shares":64866},"source":{"system":"sec-edgar","filing":"0001586785-26-000004","document":"form4-03312026_080315.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000158678526000004/form4-03312026_080315.xml","form_type":"4"}},{"id":823945,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-31T20:11:19.000Z","date":"2026-03-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":21892,"price":13.89,"value":304079.88,"ownership":{"direct":true},"balance_after":90114,"source":{"system":"sec-edgar","filing":"0001586785-26-000004","document":"form4-03312026_080315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000158678526000004/form4-03312026_080315.xml","form_type":"4"}},{"id":823944,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-31T20:11:19.000Z","date":"2026-03-28","kind":"exercise","planned":false,"acquired":true,"shares":64866,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":112006,"source":{"system":"sec-edgar","filing":"0001586785-26-000004","document":"form4-03312026_080315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000158678526000004/form4-03312026_080315.xml","form_type":"4"}},{"id":873590,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T21:20:57.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":286000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":286000,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":286000},"source":{"system":"sec-edgar","filing":"0001586785-26-000002","document":"form4-03022026_090353.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000158678526000002/form4-03022026_090353.xml","form_type":"4"}},{"id":1119006,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-09T20:10:02.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":16500,"derivative":{"exercise_price":19.53,"exercise_date":"2026-06-05","expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-25-016222","document":"form4-06092025_080657.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588925016222/form4-06092025_080657.xml","form_type":"4"}},{"id":1186022,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-01T20:01:04.000Z","date":"2025-03-28","kind":"exercise","planned":false,"acquired":true,"shares":64867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 194,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":129733,"derivative":{"underlying":"Common Stock","underlying_shares":64867},"source":{"system":"sec-edgar","filing":"0001578563-25-000197","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856325000197/primary_doc.xml","form_type":"4"}},{"id":1186021,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-01T20:01:04.000Z","date":"2025-03-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":17787,"price":8.46,"value":150478.02,"ownership":{"direct":true},"balance_after":47140,"source":{"system":"sec-edgar","filing":"0001578563-25-000197","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856325000197/primary_doc.xml","form_type":"4"}},{"id":1186020,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-04-01T20:01:04.000Z","date":"2025-03-28","kind":"exercise","planned":false,"acquired":true,"shares":64867,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":64927,"source":{"system":"sec-edgar","filing":"0001578563-25-000197","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856325000197/primary_doc.xml","form_type":"4"}},{"id":1290584,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-30T22:31:38.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":411000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":411000,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":411000},"source":{"system":"sec-edgar","filing":"0001578563-25-000027","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856325000027/primary_doc.xml","form_type":"4"}},{"id":1433389,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Restricted Stock Units","published_at":"2024-08-14T20:00:46.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":194600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock upon the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":194600,"derivative":{"underlying":"Common Stock","underlying_shares":194600},"source":{"system":"sec-edgar","filing":"0001578563-24-000363","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856324000363/primary_doc.xml","form_type":"4"}},{"id":1433388,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-14T20:00:46.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":500400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":500400,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":500400},"source":{"system":"sec-edgar","filing":"0001578563-24-000363","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856324000363/primary_doc.xml","form_type":"4"}},{"id":1478174,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-06-17T20:10:54.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":16500,"derivative":{"exercise_price":36.43,"exercise_date":"2025-06-13","expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-24-017155","document":"form4-06172024_080651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588924017155/form4-06172024_080651.xml","form_type":"4"}},{"id":1850843,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-06-20T20:10:09.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":11300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."}],"balance_after":11300,"derivative":{"exercise_price":36.87,"exercise_date":"2024-06-15","expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":11300},"source":{"system":"sec-edgar","filing":"0001415889-23-010036","document":"form4-06202023_080604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000141588923010036/form4-06202023_080604.xml","form_type":"4"}},{"id":1856908,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Stock","published_at":"2023-06-13T20:39:36.000Z","date":"2023-06-09","kind":"purchase","planned":false,"acquired":true,"shares":4000,"price":3.42,"value":13680.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan."}],"balance_after":13220,"source":{"system":"sec-edgar","filing":"0001628280-23-021958","document":"wk-form4_1686688763.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023021958/wk-form4_1686688763.xml","form_type":"4"}},{"id":1882814,"issuer":{"id":5413,"kind":"organization","name":"Zura Bio Ltd"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Share Option (Right to Buy)","published_at":"2023-05-23T01:18:02.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":7652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become fully exercisable on the earlier of (i) May 18, 2024 or (ii) the date of the next annual meeting of shareholders of Zura Bio Limited."}],"balance_after":7652,"derivative":{"exercise_price":5.31,"expiration_date":"2033-05-18","underlying":"Class A Ordinary Shares","underlying_shares":7652},"source":{"system":"sec-edgar","filing":"0001104659-23-063319","document":"tm2316481-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855644/000110465923063319/tm2316481-9_4seq1.xml","form_type":"4"}},{"id":1888434,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-17T11:43:23.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full on May 15, 2024, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":2.75,"exercise_date":"2024-05-15","expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001628280-23-018556","document":"wk-form4_1684323794.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023018556/wk-form4_1684323794.xml","form_type":"4"}},{"id":2013224,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T21:16:52.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":2.98,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001628280-23-003706","document":"wf-form4_167649579442477.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023003706/wf-form4_167649579442477.xml","form_type":"4"}},{"id":2089359,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Common Stock","published_at":"2022-12-12T21:22:14.000Z","date":"2022-12-09","kind":"purchase","acquired":true,"shares":2083,"price":4.42,"value":9206.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan."}],"balance_after":9220,"source":{"system":"sec-edgar","filing":"0001628280-22-031725","document":"wf-form4_167088011975647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022031725/wf-form4_167088011975647.xml","form_type":"4"}},{"id":2140210,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Chairman of the Board"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-07T20:03:18.000Z","date":"2022-10-05","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full on October 5, 2023, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":3.97,"exercise_date":"2023-10-05","expiration_date":"2032-10-05","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-22-026158","document":"wf-form4_166517298305198.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022026158/wf-form4_166517298305198.xml","form_type":"4"}},{"id":2229170,"issuer":{"id":4208,"kind":"organization","name":"Celldex Therapeutics, Inc."},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-17T20:05:39.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":27200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"date","element":"transactionDate","label":"F1","text":"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third vests on the first, second and third anniversaries of the date of grant."}],"balance_after":27200,"derivative":{"exercise_price":22.48,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":27200},"source":{"system":"sec-edgar","filing":"0001493152-22-017154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/744218/000149315222017154/ownership.xml","form_type":"4"}},{"id":2338181,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:49.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":7202,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":65.19,"underlying":"Common Stock","underlying_shares":7202},"source":{"system":"sec-edgar","filing":"0001628280-22-005912","document":"wf-form4_164703375138640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005912/wf-form4_164703375138640.xml","form_type":"4"}},{"id":2338180,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:49.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":61.31,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-22-005912","document":"wf-form4_164703375138640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005912/wf-form4_164703375138640.xml","form_type":"4"}},{"id":2338179,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:49.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":56.5,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-22-005912","document":"wf-form4_164703375138640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005912/wf-form4_164703375138640.xml","form_type":"4"}},{"id":2338178,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:49.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":49.17,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001628280-22-005912","document":"wf-form4_164703375138640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005912/wf-form4_164703375138640.xml","form_type":"4"}},{"id":2338177,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:49.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":13.6,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001628280-22-005912","document":"wf-form4_164703375138640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005912/wf-form4_164703375138640.xml","form_type":"4"}},{"id":2338176,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:49.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":4167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":14.6,"underlying":"Common Stock","underlying_shares":4167},"source":{"system":"sec-edgar","filing":"0001628280-22-005912","document":"wf-form4_164703375138640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005912/wf-form4_164703375138640.xml","form_type":"4"}},{"id":2338175,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T16:22:49.000Z","date":"2022-03-11","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an \"Issuer Option\") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the \"Issuer Stock Plans\") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":14.6,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001628280-22-005912","document":"wf-form4_164703375138640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005912/wf-form4_164703375138640.xml","form_type":"4"}},{"id":2338174,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-11T16:22:49.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":3067,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an \"Issuer RSU\"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-22-005912","document":"wf-form4_164703375138640.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005912/wf-form4_164703375138640.xml","form_type":"4"}},{"id":2338173,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-11T16:22:49.000Z","date":"2022-03-11","kind":"other","acquired":false,"shares":8150,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. (\"Parent\") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger (the \"Merger\") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock, $0.0001 par value per share (\"Issuer Common Stock\"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the \"Merger Consideration\"), subject to any required withholding of taxes."}],"balance_after":3067,"source":{"system":"sec-edgar","filing":"0001628280-22-005912","document":"wf-form4_164703375138640.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828022005912/wf-form4_164703375138640.xml","form_type":"4"}},{"id":2339421,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-10T22:38:08.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date."}],"balance_after":1000000,"derivative":{"exercise_price":0.7,"expiration_date":"2032-03-08","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001578563-22-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000157856322000005/primary_doc.xml","form_type":"4"}},{"id":2472969,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-12-14T22:15:35.000Z","date":"2021-12-10","kind":"purchase","acquired":true,"shares":4267,"price":1.57,"value":6699.19,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan."}],"balance_after":85639,"source":{"system":"sec-edgar","filing":"0001879785-21-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000187978521000037/edgar.xml","form_type":"4"}},{"id":2669030,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T17:22:22.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":7202,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 11, 2021 with the final installment vesting  upon the earlier of the one-year anniversary of the grant date or the date of the next annual stockholders' meeting, and are exercisable once vested."}],"balance_after":7202,"derivative":{"exercise_price":65.19,"expiration_date":"2028-06-11","underlying":"Common Stock","underlying_shares":7202},"source":{"system":"sec-edgar","filing":"0001628280-21-012275","document":"wf-form4_162379209349432.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021012275/wf-form4_162379209349432.xml","form_type":"4"}},{"id":2669029,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T17:22:22.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":3067,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 11, 2022, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":11217,"source":{"system":"sec-edgar","filing":"0001628280-21-012275","document":"wf-form4_162379209349432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000162828021012275/wf-form4_162379209349432.xml","form_type":"4"}},{"id":2669738,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-06-14T21:04:05.000Z","date":"2021-06-10","kind":"purchase","acquired":true,"shares":3692,"price":2.28,"value":8417.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan."}],"balance_after":81372,"source":{"system":"sec-edgar","filing":"0001192482-21-000501","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000119248221000501/edgar.xml","form_type":"4"}},{"id":2891886,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-28T21:07:43.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date."}],"balance_after":260000,"derivative":{"exercise_price":3.32,"expiration_date":"2031-01-26","underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001192482-21-000118","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000119248221000118/edgar.xml","form_type":"4"}},{"id":2946033,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-12-14T21:06:33.000Z","date":"2020-12-10","kind":"purchase","acquired":true,"shares":3599,"price":2.278,"value":8198.522,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan."}],"balance_after":77680,"source":{"system":"sec-edgar","filing":"0001192482-20-000816","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000119248220000816/edgar.xml","form_type":"4"}},{"id":3109527,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-16T19:46:51.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 12, 2020, and are exercisable once vested."}],"balance_after":5000,"derivative":{"exercise_price":61.31,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-037106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037106/doc4.xml","form_type":"4"}},{"id":3109526,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-16T19:46:51.000Z","date":"2020-06-12","kind":"grant","acquired":true,"shares":2446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 12, 2021, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units."}],"balance_after":8150,"source":{"system":"sec-edgar","filing":"0001209191-20-037106","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120037106/doc4.xml","form_type":"4"}},{"id":3112969,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-06-12T01:02:46.000Z","date":"2020-06-10","kind":"purchase","acquired":true,"shares":1799,"price":2.278,"value":4098.122,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan."}],"balance_after":74081,"source":{"system":"sec-edgar","filing":"0001192482-20-000484","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000119248220000484/edgar.xml","form_type":"4"}},{"id":3288181,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-05T21:38:34.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments, subject to the reporting person's continued service on each such vesting date."}],"balance_after":800000,"derivative":{"exercise_price":3.98,"expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001104659-20-011267","document":"tm206826d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000110465920011267/tm206826d2_4.xml","form_type":"4"}},{"id":3288180,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-05T21:38:34.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":72282,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 2,164,150 shares of Aevi Genomic Medicine, Inc. (\"Aevi\") common stock in connection with the merger of Aevi into a wholly owned subsidiary of the issuer pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Aevi, Genie Merger Sub, Inc., Second Merger Sub, LLC and the issuer."}],"balance_after":72282,"source":{"system":"sec-edgar","filing":"0001104659-20-011267","document":"tm206826d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000110465920011267/tm206826d2_4.xml","form_type":"4"}},{"id":3289081,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:11:32.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":261000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.55,"expiration_date":"2028-04-17","underlying":"Common Stock","underlying_shares":261000},"source":{"system":"sec-edgar","filing":"0001192482-20-000109","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000109/edgar.xml","form_type":"4"}},{"id":3289080,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:11:32.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option, which became exercisable on May 14, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.51,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001192482-20-000109","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000109/edgar.xml","form_type":"4"}},{"id":3289079,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Warrant (Right to Purchase)","published_at":"2020-02-05T16:11:32.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":13334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void."}],"balance_after":0,"derivative":{"exercise_price":2.84,"expiration_date":"2022-10-17","underlying":"Common Stock","underlying_shares":13334},"source":{"system":"sec-edgar","filing":"0001192482-20-000109","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000109/edgar.xml","form_type":"4"}},{"id":3289078,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:11:32.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option, which became exercisable beginning on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.32,"expiration_date":"2027-08-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001192482-20-000109","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000109/edgar.xml","form_type":"4"}},{"id":3289077,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:11:32.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":4.91,"expiration_date":"2027-02-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001192482-20-000109","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000109/edgar.xml","form_type":"4"}},{"id":3289076,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:11:32.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":4.83,"expiration_date":"2026-04-15","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001192482-20-000109","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000109/edgar.xml","form_type":"4"}},{"id":3289075,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:11:32.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":7.01,"expiration_date":"2025-02-18","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001192482-20-000109","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000109/edgar.xml","form_type":"4"}},{"id":3289074,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:11:32.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":13532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which became exercisable on April 16, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":6.45,"expiration_date":"2024-04-16","underlying":"Common Stock","underlying_shares":13532},"source":{"system":"sec-edgar","filing":"0001192482-20-000109","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000109/edgar.xml","form_type":"4"}},{"id":3289073,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2020-02-05T16:11:32.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger."}],"balance_after":0,"derivative":{"exercise_price":4.22,"expiration_date":"2023-09-13","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001192482-20-000109","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000109/edgar.xml","form_type":"4"}},{"id":3289072,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-02-05T16:11:32.000Z","date":"2020-02-03","kind":"disposition_to_issuer","acquired":false,"shares":2164150,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. (\"Cerecor\"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the \"Merger\").  At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001192482-20-000109","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248220000109/edgar.xml","form_type":"4"}},{"id":3348348,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-12-09T21:12:46.000Z","date":"2019-12-05","kind":"purchase","acquired":true,"shares":2049376,"price":0.134,"value":274616.384,"ownership":{"direct":true},"balance_after":2164150,"source":{"system":"sec-edgar","filing":"0001192482-19-000511","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248219000511/edgar.xml","form_type":"4"}},{"id":3488361,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-17T18:48:41.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2019, and are exercisable once vested."}],"balance_after":5000,"derivative":{"exercise_price":56.5,"expiration_date":"2026-06-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-19-037495","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037495/doc4.xml","form_type":"4"}},{"id":3488360,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-17T18:48:41.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":2654,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 13, 2020, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units."}],"balance_after":5704,"source":{"system":"sec-edgar","filing":"0001209191-19-037495","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119037495/doc4.xml","form_type":"4"}},{"id":3708125,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-03T16:27:27.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":14534.884,"price":0.86,"value":12500.00024,"ownership":{"direct":true},"balance_after":36759.211,"source":{"system":"sec-edgar","filing":"0001179110-19-000215","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911019000215/edgar.xml","form_type":"4"}},{"id":3800908,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T17:02:11.000Z","date":"2018-10-01","kind":"grant","acquired":true,"shares":8333.333,"price":1.5,"value":12499.9995,"ownership":{"direct":true},"balance_after":22224.327,"source":{"system":"sec-edgar","filing":"0001179110-18-011928","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911018011928/edgar.xml","form_type":"4"}},{"id":3874529,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-03T11:05:35.000Z","date":"2018-07-02","kind":"grant","acquired":true,"shares":808.016,"price":15.47,"value":12500.00752,"ownership":{"direct":true},"balance_after":13890.994,"source":{"system":"sec-edgar","filing":"0001179110-18-009271","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911018009271/edgar.xml","form_type":"4"}},{"id":3890956,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-06-18T16:26:31.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":261000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option award was granted on April 17, 2018 and was subject to forfeiture if stockholder approval of a proposed amendment to the Issuer's stock incentive plan to increase the number of shares reserved for issuance under the plan was not obtained. The Issuer's stockholders approved the amendment to the Issuer's stock incentive plan at the Issuer's annual meeting of stockholders on June 14, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on April 17, 2019, then in 24 equal monthly installments on the 17th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."}],"balance_after":261000,"derivative":{"exercise_price":1.55,"expiration_date":"2028-04-17","underlying":"Common Stock","underlying_shares":261000},"source":{"system":"sec-edgar","filing":"0001192482-18-000303","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000303/edgar.xml","form_type":"4"}},{"id":3892872,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-15T16:32:51.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2018, and are exercisable once vested."}],"balance_after":5000,"derivative":{"exercise_price":49.17,"expiration_date":"2025-06-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-18-038076","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118038076/doc4.xml","form_type":"4"}},{"id":3892871,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-15T16:32:51.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":3050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The amount represents restricted stock units that vest in full on the earliest of June 13, 2019, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units."}],"balance_after":3050,"source":{"system":"sec-edgar","filing":"0001209191-18-038076","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118038076/doc4.xml","form_type":"4"}},{"id":3931155,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-05-16T16:26:06.000Z","date":"2018-05-14","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on May 14, 2019, then in 24 equal monthly installments on the 14th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."}],"balance_after":300000,"derivative":{"exercise_price":1.51,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001192482-18-000221","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000221/edgar.xml","form_type":"4"}},{"id":3931154,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2018-05-16T16:21:27.000Z","date":"2017-08-11","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects a reduction in the number of shares purchaseable under the stock option.  A portion of the originally granted amount was void due to having exceeded certain plan limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects a reduction in the number of shares purchaseable under the stock option.  A portion of the originally granted amount was void due to having exceeded certain plan limitations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a reduction in the number of shares purchaseable under the stock option.  A portion of the originally granted amount was void due to having exceeded certain plan limitations."}],"balance_after":100000,"derivative":{"exercise_price":1.32,"expiration_date":"2027-08-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001192482-18-000220","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248218000220/edgar.xml","form_type":"4/A","original_submission_date":"2017-08-15"}},{"id":3936787,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-05-11T16:17:06.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in a series of three successive equal annual installments beginning on May 10, 2019."}],"balance_after":7500,"derivative":{"exercise_price":17.2,"expiration_date":"2028-05-09","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-18-006644","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911018006644/edgar.xml","form_type":"4"}},{"id":3972284,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-03T16:46:52.000Z","date":"2018-04-02","kind":"grant","acquired":true,"shares":715.512,"price":17.47,"value":12499.99464,"ownership":{"direct":true},"balance_after":13082.978,"source":{"system":"sec-edgar","filing":"0001179110-18-005240","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911018005240/edgar.xml","form_type":"4"}},{"id":4107169,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-04T12:40:15.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":1090.75,"price":11.46,"value":12499.995,"ownership":{"direct":true},"balance_after":12367.466,"source":{"system":"sec-edgar","filing":"0001179110-18-000482","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911018000482/edgar.xml","form_type":"4"}},{"id":4184110,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Warrant (right to buy)","published_at":"2017-10-18T16:16:27.000Z","date":"2017-10-17","kind":"purchase","acquired":true,"shares":13344,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13344,"derivative":{"exercise_price":2.84,"exercise_date":"2017-10-17","expiration_date":"2022-10-17","underlying":"Common Stock","underlying_shares":13344},"source":{"system":"sec-edgar","filing":"0001144204-17-053027","document":"tv477166_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000114420417053027/tv477166_4.xml","form_type":"4"}},{"id":4184109,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-10-18T16:16:27.000Z","date":"2017-10-17","kind":"purchase","acquired":true,"shares":75000,"price":1.26,"value":94500.0,"ownership":{"direct":true},"balance_after":114774,"source":{"system":"sec-edgar","filing":"0001144204-17-053027","document":"tv477166_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000114420417053027/tv477166_4.xml","form_type":"4"}},{"id":4191927,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-04T16:06:21.000Z","date":"2017-10-02","kind":"grant","acquired":true,"shares":1574.307,"price":7.94,"value":12499.99758,"ownership":{"direct":true},"balance_after":11276.716,"source":{"system":"sec-edgar","filing":"0001179110-17-013089","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911017013089/edgar.xml","form_type":"4"}},{"id":4234128,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2017-08-15T16:16:33.000Z","date":"2017-08-11","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third  on August 11, 2018,  then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer."}],"balance_after":400000,"derivative":{"exercise_price":1.32,"expiration_date":"2027-08-11","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001144204-17-043511","document":"v473386_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000114420417043511/v473386_form4.xml","form_type":"4"}},{"id":4263781,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-05T17:50:30.000Z","date":"2017-07-03","kind":"grant","acquired":true,"shares":2376.426,"price":5.26,"value":12500.00076,"ownership":{"direct":true},"balance_after":9702.409,"source":{"system":"sec-edgar","filing":"0001179110-17-010006","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911017010006/edgar.xml","form_type":"4"}},{"id":4282566,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-06-14T19:45:03.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over one year with one twelfth vesting on July 13, 2017, and the remainder of the shares vesting monthly over the following eleven months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":150000,"derivative":{"exercise_price":1.36,"expiration_date":"2024-06-13","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-17-039979","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919117039979/doc4.xml","form_type":"4"}},{"id":4320604,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-05-15T17:02:13.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in a series of three successive equal annual installments beginning on May 12, 2018."}],"balance_after":11250,"derivative":{"exercise_price":4.29,"expiration_date":"2027-05-11","underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001179110-17-007186","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911017007186/edgar.xml","form_type":"4"}},{"id":4357906,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-05T16:58:34.000Z","date":"2017-04-03","kind":"grant","acquired":true,"shares":2551.02,"price":4.9,"value":12499.998,"ownership":{"direct":true},"balance_after":7325.983,"source":{"system":"sec-edgar","filing":"0001179110-17-005780","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911017005780/edgar.xml","form_type":"4"}},{"id":4439788,"issuer":{"id":148532,"kind":"organization","name":"Aevi Genomic Medicine, LLC","symbol":"CERC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Purchase)","published_at":"2017-02-17T17:45:59.000Z","date":"2017-02-17","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award vests and becomes exercisable in three equal installments (rounded up to the nearest whole share of common stock) on February 17, 2018, February 17, 2019 and February 17, 2020, subject to the reporting person's continued service with the issuer."}],"balance_after":200000,"derivative":{"exercise_price":4.91,"expiration_date":"2027-02-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001192482-17-000048","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1138776/000119248217000048/edgar.xml","form_type":"4"}},{"id":4450343,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-02-14T20:18:16.000Z","date":"2017-02-13","kind":"grant","acquired":true,"shares":41666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest over four months with 25% vesting on March 13, 2017, and the remainder of the shares vesting monthly over the following three months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":41666,"derivative":{"exercise_price":1.46,"expiration_date":"2024-02-13","underlying":"Common Stock","underlying_shares":41666},"source":{"system":"sec-edgar","filing":"0001209191-17-010894","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919117010894/doc4.xml","form_type":"4"}},{"id":4450342,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-02-14T20:18:16.000Z","date":"2017-02-13","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over one year with one twelfth vesting on March 13, 2017, and the remainder of the shares vesting monthly over the following eleven months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":75000,"derivative":{"exercise_price":1.46,"expiration_date":"2024-02-13","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-17-010894","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919117010894/doc4.xml","form_type":"4"}},{"id":4502194,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-04T17:03:13.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":2399.232,"price":5.21,"value":12499.99872,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On December 5, 2016, the Issuer effected a one-for-ten reverse stock split of its Common Stock (the \"Reverse Split\").  The number of securities beneficially owned by the Reporting Person has been adjusted to reflect the Reverse Split."}],"balance_after":4774.963,"source":{"system":"sec-edgar","filing":"0001179110-17-000262","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911017000262/edgar.xml","form_type":"4"}},{"id":4586420,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-04T17:02:07.000Z","date":"2016-10-03","kind":"grant","acquired":true,"shares":16447.37,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":23757.32,"source":{"system":"sec-edgar","filing":"0001179110-16-030308","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911016030308/edgar.xml","form_type":"4"}},{"id":4610848,"issuer":{"id":89585,"kind":"organization","name":"Oncternal Therapeutics, Inc.","symbol":"ONCT"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-09-06T17:02:27.000Z","date":"2016-09-01","kind":"grant","acquired":true,"shares":7309.95,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7309.95,"source":{"system":"sec-edgar","filing":"0001179110-16-029324","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1260990/000117911016029324/edgar.xml","form_type":"4"}}]}